Descripción de negocio
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.
Consejo de gestión & Consejo de supervisión
| CEO |
| Nachum Homi Shamir |
| Consejo de gestión |
| Harriss T. Currie, Dr. Charles J. Collins, Eric S. Shapiro, Nancy M. Fairchild, Randall Myers, Richard Rew, Todd C. Bennet |
| Consejo de supervisión |
| Nachum Homi Shamir, Dijuana K. Lewis, Dr. Edward A. Ogunro, Dr. Stephen L. Eck, Jim D. Kever, Kenneth A. Samet, Kevin M. McNamara, Thomas W. Erickson |
Datos de la empresa
| Nombre: |
Luminex Corp. |
| Dirección: |
12212 Technology Blvd.,Austin, Texas 78727, USA |
| Teléfono: |
+1-512-219-8020 |
| Fax: |
+1-512-219-5195 |
| E-mail: |
-
|
| Internet: |
www.luminexcorp.com |
| Industria: |
Biotechnology |
| Sector: |
Biotechnology |
| Subsector: |
Biotechnology |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
61.80% |
| Fecha de OPI: |
- |
Relación con inversores
| Nombre: |
Harriss Currie |
| IR teléfono: |
- |
| IR-fax: |
+1-512-219-6325 |
| IR e-mail: |
investor@luminexcorp.com
|
